Skip to search formSkip to main contentSkip to account menu

CC-5013

Known as: CC 5013, CC5013, CDC 501 
National Institutes of Health

Related topics

Related topics

2 relations
CDC-501

Broader (1)

lenalidomide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Lenalidomide (CC-5013; Revlimid®) Promotes Erythropoiesis in Myelodysplastic Syndromes (MDS) by CD45 Protein Tyrosine Phosphatase (PTP) Inhibition.
Lenalidomide displays erythroid and cytogenetic remitting activity in MDS that is karyotype-dependent, yielding a high response… 
2006
2006
Lenalidomide (Revlimid®, CC-5013) and Actimid™ (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo
Proc Amer Assoc Cancer Res, Volume 47, 2006 4882 Lenalidomide and CC-4047 are second generation IMiDs® having immunomodulatory… 
Review
2005
Review
2005
Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: Results of the…
5 Background: Interstitial deletion of chromosome 5q31 is the most common CTG abnormality in MDS characterized by TD-anemia and… 
2005
2005
Preliminary Results of a Phase II Study of CC-5013 (Lenalidomide, Revlimid®) in Patients with Cutaneous T-Cell Lymphoma.
Background: Mycosis fungoides (MF)/Sezary syndrome (SS) represent the most common type of cutaneous T-cell lymphoma (CTCL… 
2005
2005
Phase II Study of CC-5013 (Revlimid) and Rituximab in Waldenström’s Macroglobulinemia: Preliminary Safety and Efficacy Results.
INTRODUCTION: In previous studies, we observed that CC-5013 enhanced rituximab mediated ADCC killing of lymphoplasmacytic cells… 
2005
2005
Phase II Study of Lenalidomide (CC-5013, Revlimid®) for Patients (pts) with Myelofibrosis (MF).
Introduction: Thalidomide has been shown to induce responses in pts with MF but prolonged administration in these pts may be… 
Review
2004
Review
2004
CC-5013 (Celgene).
Celgene, in collaboration with the National Cancer Institute, is developing CC-5013, the lead compound in a series of thalidomide… 
2004
2004
Anti-proliferative activity of CC-5013 in 5q- myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL) cell lines
6618 Background: Phase I/II studies of CC-5013 (Revimid™) in MDS have shown erythropoietic and cytogenetic responses, especially… 
Review
2003
Review
2003
Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience.
  • B. Barlogie
  • Seminars in hematology (Print)
  • 2003
  • Corpus ID: 3245741
Based on the activity of single-agent thalidomide in relapsed/refractory multiple myeloma in a landmark phase II study of 169… 
Review
2002
Review
2002
High-dose therapy and immunomodulatory drugs in multiple myeloma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)